Lying pigeons need something to pump their mis and disinformation so they dig into the past and try to rewrite events with their slight of hand and sometimes major misinterpretations. They never want to acknowledge any stock in the OTC that they attack is in development pre-rev stage. They heap on with big board guidelines and norms that don't apply. Such is the lay of the land in the OTC. Things are different. So, we all know this and they know it. When you don't have any truth to tell with shorts on, you must resort to fibbing and fudging and gang attacking. Never mind what the stock represents. Just lie like hell and see what sticks. The advantage they have here is the pig pharma deep pockets that use their hedge funds and rules within their SEC to hide their illegal operations. OTC stocks survive from using capital share raises until they can generate internally hopefully later qualifying for standard credit loans or receive non-shark capital infusions from the private sector.
The bare fact that CytoDyn has withstood these onslaughts is a testament to the viability and potential of leronlimab.
Now we finally have a group of dedicated company personnel who know how to succeed. The path has been clearly laid out by our CEO. Buying all significant dips always little by little. $CYDY$ 2024
ps. Covid has been lab produced to evolve so that variations and mutations continue. This is not a real virus. The importance of leronlimab grows exponentially along with exponentially changing "virus". At some point in the future, leronlimab will again be sought for this condition. Until then, proving up it's efficacy in other indications will pave the way for it's future use in mutating Covid (along with a staggering growth in long Covid aa well as many other conditions/indications.)
Bullish
News 
Market Data 
Discover 
AI
